Overview
Diabetes Mellitus: Prevention strategies, predictors, treatment effects; kidney and other complications including cardiovascular outcomes. Utilization of EHR data to construct tools to improve the care of diabetes and comorbid conditions.
Current Duke Appointments & Affiliations
Professor of Medicine
·
2021 - Present
Medicine, Endocrinology, Metabolism, and Nutrition,
Medicine
Member in the Duke Clinical Research Institute
·
2008 - Present
Duke Clinical Research Institute,
Institutes and Centers
Recent Scholarly Works
Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE Trial.
Journal article Diabetes Obes Metab · September 2026 AIMS: This prespecified analysis evaluated whether the safety and efficacy of finerenone and a sodium-glucose cotransporter 2 inhibitor (SGLT2i) combination vary by baseline glycated haemoglobin (HbA1c). MATERIALS AND METHODS: Adults with type 2 diabetes a ... Full text Link to item Cite2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Journal article Circulation · July 28, 2026 AIM: The "2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome" retires, replaces, and expands upon the "2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity ... Full text Link to item CiteA Validated, Modifiable Proteomic Score from the EXSCEL Trial Predicts Cardiovascular Events in Diabetes.
Journal article JCI Insight · July 2, 2026 Adults with type 2 diabetes mellitus (T2DM) are at increased risk for stroke, myocardial infarction, and cardiovascular death, yet individual risk is heterogeneous and incompletely captured by clinical models. In the Exenatide Study of Cardiovascular Event ... Full text Link to item CiteRecent Grants
GentiBio_GNTI-122-T1D-1001
Clinical TrialPrincipal Investigator · Awarded by GentiBio, Inc. · 2025 - 2035A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 with Recent Onset Stage 3 Type 1 Diabetes
Clinical TrialPrincipal Investigator · Awarded by COUR Pharmaceuticals Development Co., Inc. · 2025 - 2034Endocrinology and Metabolism Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2024 - 2029View All Grants
Education
University of Virginia ·
1993
M.D.